NervGen Pharma will host a virtual investor event on April 9, 2025, featuring key opinion leaders to discuss the unmet medical needs and treatment landscape for spinal cord injury patients.
NervGen Pharma's CMO, Dr. Daniel Mikol, will present at the U2FP Symposium, addressing challenges in translating SCI animal model results to human clinical trials.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.